Description
INVITROLIZE commercializes ALIsens®, developed in Luxembourg by LIST, the only available test to identify respiratory sensitizers. Currently industry has no way to predict already early in product development the hazard that a new inhalable material may induce respiratory sensitization. However, respiratory sensitization is a serious problem as more than 300 million people are globally affected by asthma and other sensitization related diseases.